Alpha-asarone improves striatal cholinergic function and locomotor hyperactivity in Fmr1 knockout mice.

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Hyperactivity is a common symptom in neurological and psychiatric disorders like Fragile X syndrome (FXS).
• The Fmr1 knockout (KO) mouse is a validated animal model for studying FXS, exhibiting significant locomotor hyperactivity.
• Alpha-asarone (α-asarone) is a bioactive compound from Acorus gramineus with demonstrated benefits for central nervous system disorders.

Purpose of the Study:

• To investigate the potential of α-asarone in alleviating locomotor hyperactivity in Fmr1 KO mice.
• To elucidate the underlying neurobiological mechanisms of α-asarone's effects, focusing on the cholinergic system.

Main Methods:

• Assessment of locomotor activity in Fmr1 KO mice treated with α-asarone.
• Measurement of cholinergic markers, including m1 muscarinic acetylcholine receptor (m1 mAChR) expression, acetylcholinesterase (AChE) activity, and acetylcholine (ACh) levels in the striatum.
• In vitro analysis of α-asarone's AChE inhibitory activity.

Main Results:

• Fmr1 KO mice displayed reduced m1 mAChR expression, elevated AChE activity, and decreased ACh levels in the striatum.
• α-asarone treatment normalized m1 mAChR expression and ACh levels, while attenuating the increased AChE activity.
• α-asarone demonstrated dose-dependent inhibition of AChE activity in vitro.

Conclusions:

• α-asarone effectively alleviates locomotor hyperactivity in the Fmr1 KO mouse model.
• The therapeutic effects are likely mediated by direct inhibition of AChE activity and upregulation of striatal m1 mAChR expression.
• These findings contribute to understanding the neurobiological basis of hyperactivity in FXS and suggest α-asarone as a potential therapeutic agent.